News | March 30, 2024
Aragen operationalizes first phase of its US$ 30 million Biologics manufacturing facility in India
Executes the first project for developing and manufacturing a novel anticancer mAb
Executes the first project for developing and manufacturing a novel anticancer mAb
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The investment will catalyse various components of the IndiaAI Mission
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
A 'better for you' organic brand spanning Food & Beverages and Nutraceutical categories
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Subscribe To Our Newsletter & Stay Updated
